<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802759</url>
  </required_header>
  <id_info>
    <org_study_id>CO42867</org_study_id>
    <secondary_id>2020-004889-19</secondary_id>
    <nct_id>NCT04802759</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer</brief_title>
  <official_title>A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants&#xD;
      with breast cancer. The current cohort (Cohort 1) will focus on participants with inoperable,&#xD;
      locally advanced or metastatic, estrogen receptor (ER)-positive breast cancer who had disease&#xD;
      progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor&#xD;
      (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting.&#xD;
      The study is designed with the flexibility to open new treatment arms as new treatments&#xD;
      become available, close existing treatment arms that demonstrate minimal clinical activity or&#xD;
      unacceptable toxicity, or modify the patient population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Objective Response, Defined as a Complete or Partial Response, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)</measure>
    <time_frame>From Baseline until disease progression (up to 6 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)</measure>
    <time_frame>From Baseline until 30 days after the last dose of study drug (up to 6 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Giredestrant at Specified Timepoints</measure>
    <time_frame>Day 1 of Cycles 1, 2, 4, 8, and 16 (each cycle is 28 days), and at treatment discontinuation visit (within 30 days after last dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Abemaciclib at Specified Timepoints</measure>
    <time_frame>Days 1 and 15 of Cycle 1; Day 1 of Cycles 2 and 3 (each cycle is 28 days), and at treatment discontinuation visit (within 30 days after last dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Ipatasertib at Specified Timepoints</measure>
    <time_frame>Days 1 and 15 of Cycle 1; Day 1 of Cycles 2 and 3 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Inavolisib at Specified Timepoints</measure>
    <time_frame>Days 1 and 15 of Cycle 1; Day 1 of Cycles 2 and 3 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Ribociclib at Specified Timepoints</measure>
    <time_frame>Days 1 and 15 of Cycle 1; Day 1 of Cycle 2 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Concentration of Everolimus at Specified Timepoints</measure>
    <time_frame>Days 1 and 15 of Cycle 1; Day 1 of Cycle 2 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1</measure>
    <time_frame>From randomization to the date of the first recorded occurrence of disease progression or death from any cause, whichever occurs first (up to 6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate, Defined as the Percentage of Participants with Stable Disease for ≥12 Weeks or a Complete or Partial Response, as Determined by the Investigator According to RECIST v1.1</measure>
    <time_frame>From Baseline until disease progression (up to 6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate, Defined as the Percentage of Participants with Stable Disease for ≥24 Weeks or with Confirmed Complete or Partial Response, as Determined by the Investigator According to RECIST v1.1</measure>
    <time_frame>From Baseline until disease progression (up to 6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization to death from any cause (up to 6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response, as Determined by the Investigator According to RECIST v1.1</measure>
    <time_frame>From first occurrence of a document objective response to the first date of recorded disease progression or death from any cause, whichever occurs first (up to 6 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Giredestrant Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Giredestrant + Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Giredestrant + Ipatasertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Giredestrant + Inavolisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Giredestrant + Ribociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Giredestrant + Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Giredestrant</intervention_name>
    <description>30 milligrams (mg) orally once a day during each 28-day cycle until unacceptable toxicity or disease progression</description>
    <arm_group_label>Giredestrant + Abemaciclib</arm_group_label>
    <arm_group_label>Giredestrant + Everolimus</arm_group_label>
    <arm_group_label>Giredestrant + Inavolisib</arm_group_label>
    <arm_group_label>Giredestrant + Ipatasertib</arm_group_label>
    <arm_group_label>Giredestrant + Ribociclib</arm_group_label>
    <arm_group_label>Giredestrant Monotherapy</arm_group_label>
    <other_name>GDC-9545</other_name>
    <other_name>RO7197597</other_name>
    <other_name>RG6171</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>150 mg orally twice a day during each 28-day cycle until unacceptable toxicity or disease progression</description>
    <arm_group_label>Giredestrant + Abemaciclib</arm_group_label>
    <other_name>Verzenio™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib</intervention_name>
    <description>400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression</description>
    <arm_group_label>Giredestrant + Ipatasertib</arm_group_label>
    <other_name>GDC-0068</other_name>
    <other_name>RO5532961</other_name>
    <other_name>RG7440</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inavolisib</intervention_name>
    <description>9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression</description>
    <arm_group_label>Giredestrant + Inavolisib</arm_group_label>
    <other_name>GDC-0077</other_name>
    <other_name>RO7113755</other_name>
    <other_name>RG6114</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression</description>
    <arm_group_label>Giredestrant + Ribociclib</arm_group_label>
    <other_name>Kisqali®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression</description>
    <arm_group_label>Giredestrant + Everolimus</arm_group_label>
    <other_name>Afinitor®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria for Cohort 1:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Documented estrogen receptor-positive (ER+) tumor&#xD;
&#xD;
          -  Patients for whom endocrine therapy is recommended and treatment with cytotoxic&#xD;
             chemotherapy is not indicated at time of entry into the study, as per national or&#xD;
             local treatment guidelines&#xD;
&#xD;
          -  Radiologic/objective evidence of recurrence or progression after the most recent&#xD;
             systemic therapy for breast cancer&#xD;
&#xD;
          -  Disease progression during or after first- or second-line hormonal therapy for locally&#xD;
             advanced or metastatic disease (note: at least one line of therapy must have contained&#xD;
             a CDK4/6i administered for a minimum of 8 weeks prior to disease progression.)&#xD;
&#xD;
          -  Postmenopausal status for women&#xD;
&#xD;
          -  Life expectancy ≥3 months&#xD;
&#xD;
          -  Availability of a representative tumor specimen that is suitable for evaluation of&#xD;
             Ki67, and/or additional biomarkers via central testing&#xD;
&#xD;
          -  Prior fulvestrant therapy is allowed&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  For patients receiving therapeutic anticoagulation: stable anticoagulant regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria for Cohort 1:&#xD;
&#xD;
          -  Known HER2-positive breast cancer&#xD;
&#xD;
          -  Prior treatment with cytotoxic chemotherapy for metastatic breast cancer&#xD;
&#xD;
          -  Concurrent hormone replacement therapy&#xD;
&#xD;
          -  Prior treatment with any of the protocol-specified study treatments&#xD;
&#xD;
          -  Treatment with investigational therapy within 28 days prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Systemic treatment for ER+ breast cancer within 2 weeks of Cycle 1, Day 1 or 5&#xD;
             half-lives of the drug prior to Cycle 1, Day 1&#xD;
&#xD;
          -  Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1 or&#xD;
             better, with the exception of alopecia of any grade and Grade ≤2 peripheral neuropathy&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  Major surgical procedure other than for diagnosis within 4 weeks prior to initiation&#xD;
             of study treatment or anticipation of need for a major surgical procedure during the&#xD;
             course of the study&#xD;
&#xD;
          -  History of malignancy other than breast cancer within 2 years prior to screening, with&#xD;
             the exception of those with a negligible risk of metastasis or death&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures&#xD;
&#xD;
          -  Uncontrolled tumor-related pain&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)&#xD;
             metastases&#xD;
&#xD;
          -  History of leptomeningeal disease&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to initiation of study treatment&#xD;
&#xD;
          -  Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation&#xD;
             of study treatment&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest computed tomography scan&#xD;
&#xD;
          -  Active cardiac disease or history of cardiac dysfunction&#xD;
&#xD;
          -  Positive HIV test at screening or at any time prior to screening&#xD;
&#xD;
          -  Active Hepatitis B or Hepatitis C virus infection&#xD;
&#xD;
          -  Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major&#xD;
             upper gastrointestinal (GI) surgery, including gastric resection, potentially&#xD;
             affecting enteral absorption&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any of the study drugs or any of their excipients&#xD;
&#xD;
        Giredestrant + Ipatasertib Arm Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with an Akt inhibitor&#xD;
&#xD;
          -  Grade ≥2 uncontrolled or untreated hypercholesterolemia or hypertriglyceremia&#xD;
&#xD;
          -  History of Type 1 or Type 2 diabetes mellitus requiring insulin&#xD;
&#xD;
          -  Congenital long QT syndrome or screening QTcF &gt;480 milliseconds&#xD;
&#xD;
          -  History or presence of an abnormal electrocardiogram (ECG) that is clinically&#xD;
             significant in the investigator's opinion&#xD;
&#xD;
          -  Treatment with strong CYP3A4 inducers and inhibitors within 4 weeks or 5&#xD;
             drug-elimination half-lives, whichever is longer, prior to initiation of study drug&#xD;
&#xD;
        Giredestrant + Abemaciclib Arm Exclusion Criteria:&#xD;
&#xD;
          -  Interstitial lung disease or severe dyspnea at rest or requiring oxygen therapy&#xD;
&#xD;
          -  History of major surgical resection involving the stomach or small bowel, or a&#xD;
             preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea&#xD;
&#xD;
          -  History of syncope of cardiovascular etiology, ventricular arrhythmia, or sudden&#xD;
             cardiac arrest&#xD;
&#xD;
        Giredestrant + Inavolisib Arm Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any PI3K, Akt, or mTOR inhibitor, or any agent whose mechanism of&#xD;
             action is to inhibit the PI3K/Akt/mTOR pathway&#xD;
&#xD;
          -  Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or&#xD;
             any history of Type 1 diabetes&#xD;
&#xD;
          -  Fasting glucose ≥126 mg/dL or ≥7.0 mmol/L and HbA1c ≥5.7%&#xD;
&#xD;
          -  Any concurrent ocular or intraocular condition that, in the opinion of the&#xD;
             investigator, would require medical or surgical intervention during the study period&#xD;
             to prevent or treat vision loss that might result from that condition&#xD;
&#xD;
          -  Active inflammatory or infectious conditions in either eye or history of idiopathic or&#xD;
             autoimmune-associated uveitis in either eye&#xD;
&#xD;
          -  Symptomatic active lung disease, including pneumonitis&#xD;
&#xD;
          -  Inability to confirm biomarker eligibility based on valid results from either central&#xD;
             testing of blood or local testing of blood or tumor tissue that documents one of the&#xD;
             protocol-defined PIK3CA mutations&#xD;
&#xD;
        Giredestrant + Ribociclib Arm Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving any of the following substances within 7 days before&#xD;
             randomization: concomitant medications, herbal supplements, and/or fruits that are&#xD;
             known as strong inhibitors or inducers of CYP3A4/5 or medications that have a narrow&#xD;
             therapeutic window and are predominantly metabolized through CYP3A4/5&#xD;
&#xD;
          -  Currently receiving or has received systemic corticosteroids ≤2 weeks prior to&#xD;
             starting trial treatment&#xD;
&#xD;
          -  Impairment of GI function or GI disease that may significantly alter the absorption of&#xD;
             the oral trial treatments&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: CO42867 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute (SCI)</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center (UMMC)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital;Medical Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peninsula Private Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Maccallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin MC; Davidof Center - Oncology Institute</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5211401</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center; Movement Disorder</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal Ensayos Clínicos START</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Anatomia Patologica</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).&#xD;
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

